You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


First patient receives low-dose psilocybin in rare headache disorder trial

Oxford-headquartered Beckley Psytech has announced the first patient has been dosed in a ‘world-first’ clinical trial evaluating the effects of psilocybin for the treatment of short-lasting unilateral neuralgiform headache attacks (SUNHA).